


JP

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/645,250
		Filing Date	August 20, 2003
		First Named Inventor	Mahajan et al.
		Group Art Unit	1636
		Examiner Name	Ramin Akhavan
Total Number of Pages in This Submission	7 pages and 58 cited references	Attorney Docket Number	57953/1151

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> A copy of the Notice to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed, prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08 (5 pages) (in duplicate) 58 references (i.e. Reference Cite Nos. #3-60)
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 14-1138 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Noreen L. Connolly Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (585) 263-1597 Fax: (585) 263-1600
Signature	<i>Noreen L. Connolly</i> Registration No. 48,987
Date	February 8, 2006

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____	
<u>2/8/06</u> Date	<u>Mary Burke</u> Signature Mary Burke Typed or printed name



Applicants : Mahajan et al.

Serial No. : 10/645,250

Cnfrm. No. : 7913

Filed : August 20, 2003

For : NIF-1 IS A NOVEL CO-TRANSDUCER THAT INTERACTS WITH AND REGULATES THE ACTIVITY OF THE NUCLEAR HORMONE RECEPTOR CO-ACTIVATOR, NRC

Examiner:
Ramin Akhavan

Art Unit:
1636

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the references listed on the attached PTO/SB/08 form.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii) , copies of the cited U.S. patents (i.e., Reference Cite Nos. 1-2) are not enclosed. Copies of the other listed references (i.e., Reference Cite Nos. 3-60) are enclosed herewith.

Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required. If additional fees are required, however, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 14-1138.

Respectfully submitted,


Date: February 8, 2006

Noreen L. Connolly
Registration No. 48,987

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1597
Facsimile: (585) 263-1600
R849981.1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
 Commissioner for Patents P.O. Box 1450
 Alexandria, VA 22313-1450, on the date below.

Date 2/8/06 Mary Burke
 Mary Burke



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/645,250
Filing Date	August 20, 2003
First Named Inventor	Mahajan et al.
Art Unit	1636
Examiner Name	Ramin Akhavan
Attorney Docket Number	57953/1151

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-4,788,222		Rice et al.	
	2	US-6,335,194		Bennett et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	ANZICK et al., "AIB1, A Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer," <i>Science</i> 277:965-968 (1997)	
	4	ARANDA et al., "Nuclear Hormone Receptors and Gene Expression," <i>Physiol. Rev.</i> 81:1269-1304 (2001)	
	5	ARAVIND, "The BED Finger, A Novel DNA-Binding Domain in Chromatin-Boundary-Element-Binding Proteins and Transposases," <i>Trends Biochem. Sci.</i> 25:421-423 (2000)	
	6	BLANCO et al., "The Histone Acetylase PCAF is a Nuclear Receptor Coactivator," <i>Genes Dev.</i> 12:1638-1651 (1998)	
	7	CAIRA et al., "Cloning and Characterization of RAP250, A Novel Nuclear Receptor Coactivator," <i>J. Biol. Chem.</i> 275:5308-5317 (2000)	
	8	CHAKRAVARTI et al., "Role of CBP/P300 in Nuclear Receptor Signalling," <i>Nature</i> 383:99-103 (1996)	
	9	CHEN et al., "Regulation of Transcription by a Protein Methyltransferase," <i>Science</i> 284:2174-2177 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/645,250
				Filing Date	August 20, 2003
				First Named Inventor	Mahajan et al.
				Group Art Unit	1636
				Examiner Name	Ramin Akhavan
Sheet	2	of	5	Attorney Docket Number	57953/1151

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	DARIMONT et al., "Structure and Specificity of Nuclear Receptor-Coactivator Interactions," <i>Genes Dev.</i> 12:3343-3356 (1998)	
	11	ELBASHIR et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Gene Dev.</i> 15(2):188-200 (2001)	
	12	FENG et al., "Hormone-Dependent Coactivator Binding to a Hydrophobic Cleft on Nuclear Receptors," <i>Science</i> 280:1747-1749 (1998)	
	13	FONDELL et al., "Ligand Induction of a Transcriptionally Active Thyroid Hormone Receptor Coactivator Complex," <i>Proc. Natl. Acad. Sci. USA</i> 93:8329-8333 (1996)	
	14	FORMAN et al., "Half-Site Spacing and Orientation Determines Whether Thyroid Hormone and Retinoic Acid Receptors and Related Factors Bind to DNA Response Elements as Monomers, Homodimers, or Heterodimers," <i>Mol. Endocrinol.</i> 6:429-442 (1992)	
	15	GENBANK ACCESSION NO. AAM54490 (10-SEP-2002)	
	16	GENBANK ACCESSION NO. AF245115 (24-JUN-2000)	
	17	GENBANK ACCESSION NO. AF309071 (10-SEP-2002)	
	18	GENBANK ACCESSION NO. AF395833 (16-SEP-2002)	
	19	GENBANK ACCESSION NO. AY079168 (15-SEP-2002)	
	20	GENBANK ACCESSION NO. bankit447054 (14-FEB-2002)	
	21	GENBANK ACCESSION NO. U27196 (31-MAY-1996)	
	22	GENBANK ACCESSION NO. XP_215941 (28-JAN-2003)	
	23	GYURIS et al., "Cdi1, A Human G1 and S Phase Protein Phosphatase that Associates with Cdk2," <i>Cell</i> 75:791-803 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,250
				Filing Date	August 20, 2003
				First Named Inventor	Mahajan et al.
				Group Art Unit	1636
				Examiner Name	Ramin Akhavan
Sheet	3	of	5	Attorney Docket Number	57953/1151

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	24	HADZIC et al., "A 10-Amino-Acid Sequence in the N-Terminal A/B Domain of Thyroid Hormone Receptor a is Essential for Transcriptional Activation and Interaction with the General Transcription Factor TFIIB," <i>Mol. Cell. Biol.</i> 15:4507-4517 (1995)	
	25	HANSTEIN et al., "p300 is a Component of an Estrogen Receptor Coactivator Complex," <i>Proc. Natl. Acad. Sci. USA</i> 93:11540-11545 (1996)	
	26	HARLOW et al., <i>Antibodies: A Laboratory Manual</i> , Cold Springs Harbor Laboratory, New York (1988) (Table of Contents only)	
	27	HART et al., "Evidence for an Antagonistic Relationship Between the Boundary Element-Associated Factor BEAF and the Transcription Factor DREF," <i>Chromosoma</i> 108:375-383 (1999)	
	28	HEERY et al., "A Signature Motif in Transcriptional Co-Activators Mediates Binding to Nuclear Receptors," <i>Nature</i> 387:733-736 (1997)	
	29	IWASAKI et al., "Identification and Characterization of RRM-Containing Coactivator Activator (CoAA) as TRBP-Interacting Protein, and its Splice Variant as a Coactivator Modulator (CoAM)," <i>J. Biol. Chem.</i> 276:33375-33383 (2001)	
	30	JUNG et al., "Molecular Cloning and Characterization of CAPER, A Novel Coactivator of Activating Protein-1 and Estrogen Receptors," <i>J. Biol. Chem.</i> 277:1229-1234 (2002)	
	31	KAMEI et al., "A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors," <i>Cell</i> 85:403-414 (1996)	
	32	KO et al., "Thyroid Hormone Receptor-Binding Protein, an LXXLL Motif-Containing Protein, Functions as a General Coactivator," <i>Proc. Natl. Acad. Sci. USA</i> 97:6212-6217 (2000)	
	33	LEE et al., "A Nuclear Factor, ASC-2, is a Cancer-Amplified Transcriptional Coactivator Essential for Ligand-Dependent Transactivation by Nuclear Receptors in vivo," <i>J. Biol. Chem.</i> 274:34283-34293 (1999)	
	34	LI et al., "NRIF3 is a Novel Coactivator Mediating Functional Specificity of Nuclear Hormone Receptors," <i>Mol. Cell. Biol.</i> 19:7191-7202 (1999)	
	35	LILL et al., "Binding and Modulation of p53 by p300/CBP Coactivators," <i>Nature</i> 387:823-827 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,250
				Filing Date	August 20, 2003
				First Named Inventor	Mahajan et al.
				Group Art Unit	1636
				Examiner Name	Ramin Akhavan
Sheet	4	of	5	Attorney Docket Number	57953/1151

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	36	MAHAJAN & SAMUELS, "Nuclear Hormone Receptor Coregulator: Role in Hormone Action, Metabolism, Growth, and Development," <i>Endocrine Reviews</i> 26(4):583-597 (2005)		
	37	MAHAJAN et al., "A New Family of Nuclear Receptor Coregulators That Integrate Nuclear Receptor Signaling through CREB-Binding Protein," <i>Mol. Cell Biol.</i> 20(14):5048-5063 (2000)		
	38	MAHAJAN et al., "NRC-Interacting Factor 1 Is a Novel Cotransducer That Interacts with and Regulates the Activity of the Nuclear Hormone Receptor Coactivator NRC," <i>Mol. Cell. Biol.</i> 22(19):6883-6894 (2002)		
	39	MAHAJAN et al., "The Nuclear Hormone Receptor Coactivator NRC Is a Pleiotropic Modulator Affecting Growth, Development, Apoptosis, Reproduction, and Wound Repair," <i>Mol. Cell. Biol.</i> 24(11):4994-5004 (2004)		
	40	MATZKE et al., "RNA-Based Silencing Strategies in Plants," <i>Curr. Opin. Genet. Dev.</i> 11(2):221-227 (2001)		
	41	McINERNEY et al., "Determinants of Coactivator LXXLL Motif Specificity in Nuclear Receptor Transcriptional Activation," <i>Genes Dev.</i> 12:3357-3368 (1998)		
	42	McKENNA et al., "Nuclear Receptor Coregulators: Cellular and Molecular Biology," <i>Endocr. Rev.</i> 20:321-344 (1999)		
	43	MONTGOMERY et al., "RNA as a Target of Double-Stranded RNA-Mediated Genetic Interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 95: 15502-15507 (1998)		
	44	NEUMANN et al., "Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields," <i>EMBO J.</i> 1: 841-45 (1982)		
	45	PARK et al., "Signal-Induced Transcriptional Activation by Dif Requires the dTRAP80 Mediator Module," <i>Mol. Cell. Biol.</i> 23(4):1358-1367 (2003)		
	46	PERKINS et al., "Regulation of NF-kappaB by Cyclin-Dependent Kinases Associated With the p300 Coactivator," <i>Science</i> 275:523-527 (1997)		
	47	PUIGSERVER et al., "A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis," <i>Cell</i> 92:829-839 (1998)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/645,250
				Filing Date	August 20, 2003
				First Named Inventor	Mahajan et al.
				Group Art Unit	1636
				Examiner Name	Ramin Akhavan
Sheet	5	of	5	Attorney Docket Number	57953/1151

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	48	SCHAPIRA et al., "In Silico Discovery of Novel Retinoic Acid Receptor Agonist Structures," <i>BMC Structural Biology</i> 1:1 (2001)	
	49	SCHAPIRA et al., "Rational Discovery of Novel Nuclear Hormone Receptor Antagonists," <i>PNAS</i> 97(3):1008-1013 (2000)	
	50	TABARA et al., "RNAi in C. elegans: Soaking in the Genome Sequence," <i>Science</i> 282:430-431 (1998)	
	51	TIMMONS & FIRE, "Specific Interference by Ingested dsRNA," <i>Nature</i> 395:854-855 (1998)	
	52	TORCHIA et al., "The Transcriptional Co-Activator p/CIP Binds CBP and Mediates Nuclear-Receptor Function," <i>Nature</i> 387:677-684 (1997)	
	53	TUSCHL, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2: 239-245 (2001)	
	54	WANG et al., "Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional Activation by Nuclear Hormone Receptor," <i>Science</i> 293:853-857 (2001)	
	55	WONG et al., "Electric Field Mediated Gene Transfer," <i>Biochem. Biophys. Res. Commun.</i> 107(2):584-7 (1982)	
	56	YANG et al., "A p300/CBP-Associated Factor that Competes with the Adenoviral Oncoprotein E1A," <i>Nature</i> 382:319-324 (1996)	
	57	ZAMORE et al., "RNAi: Double Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <i>Cell</i> 101:25-33 (2000)	
	58	ZHANG et al., "Two Contact Regions Between Stat1 and CBP/p300 in Interferon Gamma Signaling," <i>Proc. Natl. Acad. Sci. USA</i> 93:15092-15096 (1996)	
	59	ZHU et al., "Cloning and Characterization of PIMT, A Protein With a Methyltransferase Domain, Which Interacts With and Enhances Nuclear Receptor Coactivator PRIP Function," <i>Proc. Natl. Acad. Sci. USA</i> 98:10380-10385 (2001)	
	60	ZHU et al., "Isolation and Characterization of Peroxisome Proliferator-Activated Receptor (PPAR) Interacting Protein (PRIP) as a Coactivator for PPAR," <i>J. Biol. Chem.</i> 275:13510-13516 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.